Current Treatment Landscape for Pancreatic Cancer
Diane Simeone, MD, director of the Pancreatic Cancer Center and associate director of Translational Research at NYU Langone’s Perlmutter Cancer Center, discusses the current state of the pancreatic cancer treatment paradigm. She says it is a very exciting time for this field as there is a large body of researchers now involved.
Diane Simeone, MD, director of the Pancreatic Cancer Center and associate director of Translational Research at NYU Langone’s Perlmutter Cancer Center, discusses the current state of the pancreatic cancer treatment paradigm. She says it is a very exciting time for this field as there is a large body of researchers now involved.
Simeone says that part of this new interest in the field potentially stems from the fact that there hasn’t been a lot of change in the field for a while. There is also more funding in this field while people are increasingly becoming more aware of the rising incidences of pancreatic cancer.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
